At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 204 enrolled
Drug / intervention
OROS-Methylphenidate (MPH)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effects of ADHD Medication (TEAM) Study: Neurobehavioral Effects of Abrupt Methylphenidate Discontinuation
Children's Hospital Medical Center, Cincinnati·interventional·Posted Nov 18, 2014·Updated Dec 21, 2023
In Brief
A Phase 4 clinical trial evaluating OROS-Methylphenidate (MPH) for ADHD. Completed, enrolled 204 participants across 2 sites.
Detailed Summary
This study evaluates the effects of receiving and then discontinuing methylphenidate (MPH) in children with ADHD. After receiving MPH for 8 weeks, participants will be randomized to either discontinue MPH (and receive placebo) OR remain on MPH for 4 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsADHD
CountriesUnited States
CollaboratorsSeattle Children's Hospital
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartJan 2015
Primary CompletionJun 2020
Study CompletionJun 2021
TodayJul 2026
First PostedNov 18, 2014
Enrollment StartJan 12, 2015
Primary CompletionJun 30, 2020
Study CompletionJun 30, 2021
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 11.6 years ago
Interventions
OROS-Methylphenidate (MPH)drug
OROS-methylphenidate will be taken orally once daily at doses that have been approved for the study age group by the U.S. FDA.